CA2800038A1 - Diagnostic methods - Google Patents

Diagnostic methods Download PDF

Info

Publication number
CA2800038A1
CA2800038A1 CA2800038A CA2800038A CA2800038A1 CA 2800038 A1 CA2800038 A1 CA 2800038A1 CA 2800038 A CA2800038 A CA 2800038A CA 2800038 A CA2800038 A CA 2800038A CA 2800038 A1 CA2800038 A1 CA 2800038A1
Authority
CA
Canada
Prior art keywords
protein
polypeptide
panel
concentration
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2800038A
Other languages
English (en)
French (fr)
Inventor
Loic Gerard Dayon
Jean-Charles Sanchez
Villalonga Joan Montaner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Geneve
Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Proteome Sciences PLC
Original Assignee
Universite de Geneve
Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Electrophoretics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Geneve, Fundacio Institut de Recerca Hospital Universitari Vall dHebron, Electrophoretics Ltd filed Critical Universite de Geneve
Publication of CA2800038A1 publication Critical patent/CA2800038A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C12N9/1088—Glutathione transferase (2.5.1.18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CA2800038A 2010-05-21 2011-05-23 Diagnostic methods Abandoned CA2800038A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1008541.3A GB201008541D0 (en) 2010-05-21 2010-05-21 Diagnostic methods
GB1008541.3 2010-05-21
PCT/GB2011/000784 WO2011144914A2 (en) 2010-05-21 2011-05-23 Diagnostic methods

Publications (1)

Publication Number Publication Date
CA2800038A1 true CA2800038A1 (en) 2011-11-24

Family

ID=42341144

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2800038A Abandoned CA2800038A1 (en) 2010-05-21 2011-05-23 Diagnostic methods

Country Status (7)

Country Link
US (1) US20130252834A1 (enExample)
EP (1) EP2572202A2 (enExample)
JP (1) JP5775568B2 (enExample)
AU (1) AU2011254386B2 (enExample)
CA (1) CA2800038A1 (enExample)
GB (1) GB201008541D0 (enExample)
WO (1) WO2011144914A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012051519A2 (en) * 2010-10-14 2012-04-19 The Johns Hopkins University Biomarkers of brain injury
WO2012155134A2 (en) 2011-05-12 2012-11-15 The Johns Hopkins University Assay reagents for a neurogranin diagnostic kit
WO2013104720A2 (en) * 2012-01-12 2013-07-18 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Brain damage marker
US9709573B2 (en) 2012-03-13 2017-07-18 The Johns Hopkins University Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
EP3022322A4 (en) 2013-07-17 2017-05-17 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
CN103432574B (zh) * 2013-08-25 2015-04-08 浙江大学 一种过氧化物酶在制备防治脑血管疾病药物中的应用
WO2015038784A1 (en) * 2013-09-13 2015-03-19 The Board Of Trustees Of The Leland Stanford Junior University Multiplexed imaging of tissues using mass tags and secondary ion mass spectrometry
US20180238907A1 (en) * 2014-10-06 2018-08-23 Université de Genéve Markers and their use in brain injury
WO2017174557A2 (en) 2016-04-04 2017-10-12 Brains Online Holding B.V. Use of push pull microdialysis in combination with shotgun proteomics for analyzing the proteome in extracellular space of brain
WO2018148294A2 (en) * 2017-02-07 2018-08-16 Bioregency, Inc. S100β AND ISOFORMS FOR DETECTION OF NEUROLOGICAL CONDITIONS
CN107748263A (zh) * 2017-08-31 2018-03-02 北京臻惠康生物科技有限公司 一种纤维蛋白溶酶原的新用途及试剂盒
CN109536469B (zh) * 2018-11-23 2021-02-09 北华大学 突变改造Prx6蛋白及其表达基因、制备方法和应用
MX2022009880A (es) * 2020-02-14 2022-08-22 Galaxy Ccro Inc Dispositivos y metodos para tratar la isquemia y sindromes de dificultad respiratoria aguda.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2263063C (en) * 1999-02-26 2004-08-10 Skye Pharmatech Incorporated Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
AU2004274710B2 (en) * 2003-09-20 2011-05-19 Electrophoretics Limited Diagnostic method for brain damage-related disorders
US20080307537A1 (en) * 2005-03-31 2008-12-11 Dana-Farber Cancer Institute, Inc. Compositions and Methods for the Identification, Assessment, Prevention, and Therapy of Neurological Diseases, Disorders and Conditions
JP4521512B2 (ja) * 2005-06-15 2010-08-11 独立行政法人産業技術総合研究所 痴呆症の診断方法及び診断キット
GB2428240A (en) * 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
EP2057465A4 (en) * 2006-08-09 2010-04-21 Homestead Clinical Corp ORGANIC PROTEINS AND METHOD OF USE THEREOF

Also Published As

Publication number Publication date
JP5775568B2 (ja) 2015-09-09
AU2011254386A1 (en) 2012-12-06
AU2011254386B2 (en) 2017-01-12
EP2572202A2 (en) 2013-03-27
US20130252834A1 (en) 2013-09-26
JP2013531784A (ja) 2013-08-08
GB201008541D0 (en) 2010-07-07
WO2011144914A3 (en) 2012-03-29
WO2011144914A2 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
CA2800038A1 (en) Diagnostic methods
US9028825B2 (en) Diagnostic method for brain damage-related disorders
DK2389587T3 (en) Diagnostic and prognostic methods related Alzheimer's Disease
US8911960B2 (en) Method for identifying idiopathic pneumonia progression by measuring the level of mannose-binding protein C
Anada et al. Panel of serum protein biomarkers to grade the severity of traumatic brain injury
Streijger et al. A targeted proteomics analysis of cerebrospinal fluid after acute human spinal cord injury
Surin et al. LG 3 fragment of endorepellin is a possible biomarker of severity in I g A nephropathy
KR20200028510A (ko) 화학요법 표적에 대한 srm 검정
Thouvenot et al. Enhanced detection of CNS cell secretome in plasma protein-depleted cerebrospinal fluid
US20210396769A1 (en) Protein antigen combination, detection method and testing kit using the same
CN113544513A (zh) 用于诊断糖尿病视网膜病变的复合生物标志物及其用途
KR102547505B1 (ko) 주요 우울 장애 치료 효과 조기 예측용 바이오마커
US20180267020A1 (en) Panel of acvs-associated proteins for diagnosis and prognosis
US20100035263A1 (en) Biomarkers for renal disease
Scebba et al. Differential proteome profile in ischemic heart disease: Prognostic value in chronic angina versus myocardial infarction. A proof of concept
KR20200109618A (ko) 알츠하이머치매 진단 바이오마커
WO2012004822A1 (en) Use of melanoma biomarkers in medical and diagnostic field and method for the identification thereof
US20180067130A1 (en) Pglyrp2 biomarker in idiopathic pneumonia syndrome
KR101795595B1 (ko) 비소세포성 폐암의 혈액학적 진단 방법
Ucciferri et al. Differential proteome profile in ischemic heart disease: Prognostic value in chronic angina versus myocardial infarction. A proof of concept

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20170524